Testosterone Gel Articles

Auxilium Pharma and GlaxoSmithKline to co-promote Testim in USA

22 May 2012

Ph III results support Boehringer Ingelheim’s flibanserin as a potential female “Viagra”

17 November 2009

Endo to buy US rights to ProStrakan’s Fortesta for up to $210 million

26 August 2009

ProStrakan files response to FDA

7 May 2009

Solvay's 2008 profit drops 46%, hit by losses on Fortis holdings and forex effects

2 March 2009

Bayer signs deal for ProStrakan's Tostrex

15 December 2008

Ferring is Auxilium's new EU partner for Testim

8 December 2008

ProStrakan licenses Tostran to Bayer

1 December 2008

ProStrakan's 10-month sales jump 33%

24 November 2008

BioSante reacquires Elestrin rights

18 August 2008

BioSante gains new FDA SPA for Libigel

4 August 2008

Tostran improves insulin sensitivity and sex function

23 June 2008

ProStrakan's early-2008 sales exceed projections

2 June 2008

Solvay's 1st-qtr 2008 net income rises 1%

26 May 2008

Watson swings to profit of $38.4M in 4th qtr

3 March 2008

Solvay's 2007 income climbs just 1%

25 February 2008

ProStrakan's 2007 sales exceed expectations

21 January 2008

ProStrakan starts enrolling US Fortigen and Cellegesic trials

20 August 2007

ProStrakan's 1st-half 2007 sales jump 15%

16 July 2007

Solvay submits US sNDA for AndroGel

25 June 2007

ProStrakan launches Tostran in the UK

18 June 2007

Strong data on Bayer's Testogel and Nebido

2 April 2007

Ipsen's FY 2006 sales rise 6.8% to $1.15B

26 March 2007

BioSante swings to $2.8M income in 2006

26 March 2007

BioSante initiates Ph III trial of LibiGel

8 January 2007

ProStrakan and Ferring sign licensing deal

18 December 2006

ProStrakan buys Tostran and Rectogesic

4 December 2006

ProStrakan half-year sales up 28% to L16.1M

25 September 2006

Bentley reports 2nd-qtr 2006 EPS of $0.12

14 August 2006

ProStrakan to sell Cellegy drugs in CIS/Russia

3 July 2006

Bentley reports 33% increase in revenue

20 March 2006

Solvay's 2005 revenue reaches 8.5 B euros

27 February 2006

France's Ipsen sees 8.6% sales growth

16 May 2005

ICOS and Solvay form AndroGel alliance

7 February 2005

Tostrex granted first EU clearance in Sweden

10 January 2005

Auxilium/Ipsen's Testim OKed in EU

20 December 2004

P&G's Intrinsa rejected by FDA panel

13 December 2004

Bentley's revenues jump 21% for 3rd qtr

15 November 2004

Bentley's 2nd-qtr sales jump to all time high

9 August 2004

Cellegy and Strakan in Tostrex deal

19 July 2004

Bentley's revenues rise 15.4% for 1st-qtr 2004

10 May 2004

Auxilium and Ipsen sign Testim agreement

12 April 2004

Cellegy's revenues climb 16% in 2003

5 April 2004

Bentley's sales hit record $64.7 million

8 March 2004

Study shows long-term benefits of Testim

8 March 2004

Auxilium and Bayer sign Testim deal

9 February 2004

FDA rejects Cellegy's testosterone gel

14 July 2003

Auxilium's Testim cleared in UK

7 July 2003

Positive Testim data from landmark study

23 June 2003

Auxilium files NDA for gel-based testosterone drug

11 March 2002

Cellegy losses deepen as sales to Gryphon fall

25 February 2002

FDA filing ahead of schedule for Tostrex

8 November 2001

Cellegy claims progress with drug for women with sexual dysfunction

30 August 2001

Cellegy and PanGeo sign Tostrex deal

24 August 2001

Antares/BioSante start Ph II trial of LibiGel

8 June 2001

Unimed, TAP to copromote AndroGel

7 June 2001

Unimed files NDA for hypogonadism

16 July 1999

Solvay Group agrees to acquire Unimed Pharmaceuticals for $123 million

14 June 1999

Unimed files NDA for Androgel in USA

6 May 1999

Cellegy's Glylorin Effective in Follow-Up Indication

19 August 1998

Unimed Completes Enrollment For Ph III Androgel Trial

4 June 1998

Cellegy's Glyorin Falls At Phase III

11 March 1998

Unimed Begins Ph III With Androgel

7 April 1997

Unimed To Launch Androgel Trial

10 June 1996

Unimed Licenses Two Testosterone Products

21 August 1995

TESTOSTERONE GEL AND HEART DISEASE

23 August 1993

FTC sues Watson and Par over AndroGel deal